Gamma Knife study: patients with up to 10 brain mets

Print Friendly, PDF & Email

Update to landmark study confirms stereotactic radiosurgery (SRS) “non-inferior” to WBRT, while offering important patient benefits

Study provides further evidence in favor of Gamma Knife radiosurgery as frontline treatment in patients with 4+ brain mets – Gamma Knife SRS known for lower toxicity/side effects and fewer treatment sessions – Potential to treat and retreat a patient with Gamma Knife over a long time period

Clinicians at 23 Japanese medical centers continued to follow the still living patients enrolled in a Japanese Leksell Gamma Knife (JLGK) Society 1,194-patient study[1] over a two-year period ending on December 31, 2014.

In the original study – the results of which were published in The Lancet Oncology – the patients (enrolled between March 2009 to February 2012) had one to as many as 10 brain mets and all were treated with single-session Leksell Gamma Knife SRS. The study concluded that SRS without whole brain radiation therapy (WBRT) in patients with five to 10 brain mets was non-inferior to that in patients with two to four mets.

“Due to the clearly lower toxicity rate, they concluded that SRS should be considered a safe and effective alternative to WBRT now for patients with up to 10 brain metastases” says Joel Goldwein, M.D. Senior Vice President of Medical Affairs. “This is an extremely important study that should help drive treatment away from toxic WBRT and towards SRS for these patients.”

Follow up confirms Gamma Knife advantages

The updated study[2] expanded the follow up period of living patients to December 31, 2014.

“The follow up verifies that the steep dose fall off and precision of Gamma Knife radiosurgery can safely and effectively treat patients with very large tumor burdens,” Goldwein observes. “As we begin treating cancer as a chronic disease, these dose characteristics will allow us to safely treat and retreat patients with multiple mets over a long period of time while maintaining their quality of life.”

  1. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet Oncol 2014:15:387-395
  2. Yamamoto M, Serizawa T, Higuchi Y, et al. A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901 Study Update) : Irradiation-related complications and long-term maintenance of mini-mental state examination scores. Int J Rad Biol Phys 2017 : VOLUME # :31-40.
Next Previous Home